Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone marrow stem cell and Schwann cell transplantation for complete chronic and subacute spinal cord injury
IRCT20200502047277N8Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of bone marrow-derived mesenchymal stem cells in spinal cord injury (SCI) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: ASIA sensory score at 12 months, ASIA motor score at 12 months and 9 more. Started Jun 2022; status: completed.
02
Drugs
bone marrow-derived mesenchymal stem cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on IRCT20200502047277N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200502047277N8.